雄激素剥夺联合多西他赛放疗用于局限性高危前列腺癌的可行性 - Suppr

Feasibility of androgen-deprivation and radiation therapy with docetaxel for localized high-risk prostate cancer.

作者信息

Iwamoto Hiroaki, Izumi Kouji, Mizokami Atsushi

机构信息

Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.

出版信息

Transl Androl Urol. 2024 Jul 31;13(7):1324-1326. doi: 10.21037/tau-23-669. Epub 2024 Jun 27.

DOI:10.21037/tau-23-669

PMID:39100828

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11291412/

Abstract

摘要

相似文献

Feasibility of androgen-deprivation and radiation therapy with docetaxel for localized high-risk prostate cancer.

Transl Androl Urol. 2024 Jul 31;13(7):1324-1326. doi: 10.21037/tau-23-669. Epub 2024 Jun 27.

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Eur Urol. 2023 Aug;84(2):156-163. doi: 10.1016/j.eururo.2023.04.024. Epub 2023 May 12.

Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.

BJU Int. 2012 Dec;110(11 Pt B):E721-6. doi: 10.1111/j.1464-410X.2012.11536.x. Epub 2012 Sep 27.

Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12.

The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.

Eur Urol Oncol. 2025 Apr;8(2):296-305. doi: 10.1016/j.euo.2024.06.015. Epub 2024 Jul 20.

Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial.

Radiother Oncol. 2010 Nov;97(2):312-7. doi: 10.1016/j.radonc.2010.08.012. Epub 2010 Sep 16.

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.

J Clin Oncol. 2021 Sep 10;39(26):2938-2947. doi: 10.1200/JCO.21.00596. Epub 2021 Jul 1.

Rupture of liver metastasis in high-volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy.

IJU Case Rep. 2022 Jul 27;5(6):451-454. doi: 10.1002/iju5.12512. eCollection 2022 Nov.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer.

Rev Recent Clin Trials. 2016;11(4):317-323. doi: 10.2174/1574887111666160719145456.

本文引用的文献

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Eur Urol. 2023 Aug;84(2):156-163. doi: 10.1016/j.eururo.2023.04.024. Epub 2023 May 12.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1.

Prostate cancer-what about oligometastatic disease and stereotactic ablative radiotherapy?-a narrative review.

Ann Palliat Med. 2023 May;12(3):646-652. doi: 10.21037/apm-22-828. Epub 2023 Mar 2.

Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer.

Biomedicines. 2022 Sep 22;10(10):2369. doi: 10.3390/biomedicines10102369.

Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men.

Cancers (Basel). 2022 Oct 2;14(19):4822. doi: 10.3390/cancers14194822.

Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.

Prostate. 2021 Jan;81(1):72-80. doi: 10.1002/pros.24082. Epub 2020 Oct 13.

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer.

Diagnostics (Basel). 2020 Jul 31;10(8):549. doi: 10.3390/diagnostics10080549.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Ann Oncol. 2019 Dec 1;30(12):1992-2003. doi: 10.1093/annonc/mdz396.

Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.

Clin Lab. 2019 Jul 1;65(7). doi: 10.7754/Clin.Lab.2019.181213.

Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells.

Oncol Rep. 2019 Jul;42(1):224-230. doi: 10.3892/or.2019.7171. Epub 2019 May 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Feasibility of androgen-deprivation and radiation therapy with docetaxel for localized high-risk prostate cancer.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献